EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudie

Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study

Mariabeatrice Principi, Irene Vita Brescia, Elisa Stasi, Silvia Mazzuoli, Angela Maria D'Uggento, Elena Equatore, Ilaria Lacavalla, Alfredo Di Leo

Digestive Diseases and Sciences · 2024

DOI: 10.1007/s10620-024-08631-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Mariabeatrice Principi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, DiMePreJ, "Aldo Moro" University, Bari, Italy. b.principi@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Infliximab, Quality of Life, Gastrointestinal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedInfliximabQuality of LifeGastrointestinal AgentsInflammatory Bowel DiseasesHumansFemaleMaleAdultProspective StudiesMiddle AgedInjections, SubcutaneousTreatment OutcomeYoung AdultDrug Monitoring

Stichwörter der Autor:innen

BiobetterInfliximab SCPatient's choiceVedolizumab SC

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedInfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Gastroenterology Unit, DiMePreJ, "Aldo Moro" University, Bari, Italy. b.principi@gmail.com.
  • P.O. Di Venere, UOSVD Screening Colon Retto Endoscopia Digestiva, Bari, Italy.
  • Ospedale Vito Fazzi, UOS Gastroenterologia Ed Endoscopia Digestiva, Lecce, Italy.
  • Ospedale Di Miccoli, UOC Gastroenterologia, Barletta, Italy.
  • Department of Economics and Finance, University of Bari Aldo Moro, Bari, Italy.
  • Gastroenterology Unit, DiMePreJ, "Aldo Moro" University, Bari, Italy.

Zitieren

APA

Principi, M., Brescia, I. V., Stasi, E., Mazzuoli, S., D'Uggento, A. M., Equatore, E., Lacavalla, I., & Di Leo, A. (2024). Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08631-2

Vancouver

Principi M, Brescia IV, Stasi E, Mazzuoli S, D'Uggento AM, Equatore E, et al. Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08631-2

BibTeX
@article{Principi2024,
  author = {Principi, Mariabeatrice and Brescia, Irene Vita and Stasi, Elisa and Mazzuoli, Silvia and D'Uggento, Angela Maria and Equatore, Elena and Lacavalla, Ilaria and Di Leo, Alfredo},
  title = {Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study},
  journal = {Digestive Diseases and Sciences},
  year = {2024},
  doi = {10.1007/s10620-024-08631-2}
}
Kostenlos starten →